The combination treatment with BEN may have an additive effect on GvHD control by reducing naïve CD4 T cell numbers and frequencies in addition to the reduction of CD4 effector memory T cells seen with CY or other post-PBMC pharmacological agents presented here and previously shown in other murine GvHD models (25, 26). Here, CD4 is linked to graft versus host disease.